**Luigi Mangione Pleads Guilty to Killing UnitedHealthcare CEO Brian Thompson**
In a significant development within a high-profile federal case, Luigi Mangione, 28, has pleaded guilty to the fatal shooting of Brian Thompson, the CEO of UnitedHealthcare. The plea was entered on Friday in a federal court before US District Judge Margaret Garnett. Mangione admitted to stalking Thompson with the intent to kill, revealing the motivations behind his actions during the court proceedings.
Mangione disclosed that his decision to target Thompson stemmed from personal grievances with the health insurance system, particularly after suffering a broken back. He stated that he had conducted research on UnitedHealthcare’s annual investor conference, which led him to travel to New York with the intention of carrying out the murder. In a chilling admission, Mangione confirmed to the court, “I shot Mr. Thompson in Manhattan and he died,” detailing the premeditated nature of his crime.
The shooting occurred on December 4, 2024, outside a hotel in Manhattan where the investor conference was being held. Following the incident, Mangione was the subject of a five-day manhunt that garnered significant media attention and public interest, particularly on social media platforms where discussions about the U.S. health insurance industry intensified.
Mangione's guilty plea allows him to avoid a federal trial concerning Thompson's death. His attorney, Karen Friedman Agnifilo, indicated that there was no plea agreement with prosecutors. Judge Garnett informed Mangione that he could face a maximum sentence of life imprisonment for each of the two federal stalking charges he pleaded guilty to. Sentencing has been scheduled for December 18.
Initially, federal prosecutors had charged Mangione with murder, weapons offenses, and stalking. However, in January 2026, Judge Garnett dismissed the federal murder and weapons charges on legal grounds, which eliminated the possibility of a federal death sentence. Despite this, Mangione still faces the prospect of life imprisonment without the possibility of parole based on the remaining charges.
In addition to the federal case, Mangione is dealing with separate state charges in New York. He has pleaded not guilty to charges of murder, weapons offenses, and forgery at the state level. Notably, a state terrorism charge against him was dismissed in September 2025. His state murder trial is set to commence on September 8, 2026. If convicted of second-degree murder, Mangione could face a sentence ranging from 25 years to life in prison.
The implications of Mangione's federal guilty plea may extend to the state prosecution. His legal team may attempt to invoke New York's double jeopardy protections, which prevent an individual from being prosecuted for the same conduct in multiple jurisdictions. However, prosecutors are expected to contest this motion, arguing that the state murder charge is legally distinct from the federal charges.
As the case continues to unfold, it remains a focal point of public discourse, reflecting broader concerns regarding the health insurance industry and its impact on individuals. The outcome of both the federal and state proceedings will be closely monitored as they progress through the judicial system.